This is the English translation of the intervention delivered by the South Centre on Thursday, 23 January 2014 at the 134th session of the World Health Organization’s Executive Board expressing solidarity with the Government of the Republic of South Africa following the Pharmagate exposé.
Thank you, Madam President, for giving us the floor.
Three NGOs, Medicus Mundi International, HAI and MSF, each read statements during the EB discussions on the CEWG demonstration projects. The statements were limited to 300 words, and NGOs were required to provide the text 24 hours before the agenda item, and obtain WHO approval of the content. KEI worked with HAI on its statement, and the Peoples Health Movement worked with MMI on its statement. The text of the HAI and MMI statements follow:
Health Action International (HAI) statement to EB 134 On agenda item 9.3, follow up to CEWG on financing and coordination
The following are some quotes by countries, companies, academics and other actors stating, suggesting or implying claiming that drugs not on the WHO Model List of Essential Medicines (WHO EML) should not be subject to a compulsory license.
Bayer. Political Principles.
http://www.bayer.com/en/innovation-requires-investment.aspx
Political Principles.
Innovation requires investment.
Good ideas must be worthwhile.
On Thursday, 23 January 2014, Malebona Precious Matsoso (Director General of the South African National Department of Health) delivered the the following intervention at the 134th session of the World Health Organization’s Executive Board under agenda item 9.7 on Access to essential medicines in response to the recent Pharmagate imbroglio.
On Thursday, 23 January 2014, the South Centre delivered the following statement at the 134th session of the World Health Organization’s Executive Board under agenda item 9.7, access to essential medicines, expressing solidarity with the Government of the Republic of South Africa following the Pharmagate exposé.
GRACIAS SENORA PRESIDENTA POR DARNOS LA PALABRA.Blogs and Press coverage of Pharma/Medicine device industry lobbying on South Africa patent reform (pharmagate)
Boseley, Sarah. 17 January 2014. “South African pharma firms accused of planning to delay patents law reform.” The Guardian. http://www.theguardian.com/world/2014/jan/17/south-african-pharma-accused-delay-patents-law-reform
De Wet, Phillip. 17 January 2014. “Motsoaledi: Big pharma’s ‘satanic’ plot is genocide.” Mail & Guardian. http://mg.co.za/article/2014-01-16-motsoaledi-big-pharmas-satanic-plot-is-genocide/
Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for “western patients who can afford it.”
Bayer CEO Marijn Dekkers called the Nexavar compulsory license “essentially theft.” [UPDATE: The latest blog and transcript of Bayer CEO Marijn Dekkers’ full quote on the Indian compulsory license of Nexavar at the December Financial Times event is now available.]
New leaked Merck missive reveals deep drug, medical device company opposition to South African patent reforms
James K. Glassman. Merck said Glassman’s public relations firm was selected by PhRMA to lead a campaign to keep drug prices high in South Africa. The Health Minister in South Africa referred to the campaign proposal as a genocidal conspiracy of satanic magnitude. 2014: KEI testimony on WIPO broadcasting treaty, to House Judiciary Subcommittee on Courts, Intellectual Property, and Internet
Testimony of James Packard Love
Hearing on: The Scope of Copyright Protection
January 14, 2014
Subcommittee on Courts, Intellectual Property, and the InternetMy 10 page written statement is here: /wp-content/uploads/JamesLove_Testimony.pdf
My 5 minute oral statement follows:
James Packard Love, Opening statement
Hearing on: The Scope of Copyright Protection
January 14, 2014
Subcommittee on Courts, Intellectual Property, and the InternetWIPO hosts Conference on Open Innovation: Collaborative Projects and the Future of Knowledge (22-23 January 2014)
The World Intellectual Property Organization (WIPO) will host a “Conference on Open Innovation: Collaborative Projects and the Future of Knowledge” on 22-23 January 2014 at its headquarters in Geneva, Switzerland.
The origins of this conference on open collaborative development models is predicated upon Recommendation 36 of the WIPO Development Agenda which states:
